Explore Cutting-Edge ASI Clinical Studies
The high accuracy of the new aided karyotyping is anticipated to reduce the time spent on preparing karyograms, allowing to focus more time on chromosome analysis and reporting.
Inactivating TP53 mutations leads to a loss of function of p53, but can also often result in oncogenic gain-of-function (GOF) of mutant p53 proteins which promotes tumor development and progression.
Hexavalent chromium is a known human lung carcinogen with widespread exposure in environmental and occupational settings.
Computer-aided quantitative analysis as second opinion in the assessment of low HER2 IHC score in breast cancer – a pilot evaluation.
The Ki-67 index is critical in many malignancies’ grading that correlates to prognoses and therapeutics. However, the assessment is not standardized.
The transcription factor MYC is a well-described oncogene with an important role in lymphomagenesis, but its significance for clinical outcome in mantle cell lymphoma (MCL) remains to be determined.
Published studies report a difference in the PD-L1 positivity rate in malignant peripheral nerve sheath tumors. In this article, the authors examined PD-L1 expression and lymphocyte infiltration in patients with vestibular schwannoma.
Detection of gene rearrangements in MYC and human B-cell lymphoma 6 using fluorescence in situ hybridization (FISH) are important in the evaluation of lymphomas, in particular diffuse large B-cell lymphoma and Burkitt lymphoma.
The outcome of children and young adults with sarcoma has improved dramatically with the use of systemic chemotherapy in the context of multimodality treatment.
Quantitative imaging is a promising tool that is gaining wide use across several areas of pathology. This paper demonstrates the utility of quantitative image analysis in providing highly reliable HER2 FISH analysis.
Acute leukaemia is a heterogeneous neoplastic disease that occurs by the growth of abnormal lymphoid and myeloid cells in the bone marrow and blood leading to acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL).
The development of medicinal products often continues throughout the different phases of a clinical study and may require challenging changes in raw and starting materials at later stages. Comparability between the product properties pre- and post-change thus needs to be